BioXcel Therapeutics (BTAI) Cash from Operations (2017 - 2026)

BioXcel Therapeutics' Cash from Operations history runs 10 years deep, the most recent figure standing at 11809000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 1.94% year-over-year to 11809000.0; the TTM figure through Mar 2026 stood at 57381000.0 (up 13.54% YoY), while the FY2025 annual figure was 57615000.0, up 20.01% from the prior year.
• Cash from Operations was 11809000.0 for Q1 2026 at BioXcel Therapeutics, up from 14210000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 11809000.0 in Q1 2026 to a low of 52353000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 25399882.35 across 5 years, with a median of 23174000.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations sank 93.85% in 2022, then jumped 66.18% in 2024.
• A 5-year view of Cash from Operations shows it stood at 38639000.0 in 2022, then soared by 30.48% to 26863000.0 in 2023, then soared by 44.87% to 14809000.0 in 2024, then advanced by 4.04% to 14210000.0 in 2025, then gained by 16.9% to 11809000.0 in 2026.
• The last three Cash from Operations figures came in at 11809000.0 (Q1 2026), 14210000.0 (Q4 2025), and 18787000.0 (Q3 2025), per Business Quant data.